Gottschalk J, Goebel S, Jautzke G, Martin H, Zimmer C, Märzheuser-Brands S, Cervós-Navarro J
Institute of Neuropathology, Klinikum Steglitz, Berlin, FRG.
Histol Histopathol. 1992 Oct;7(4):653-61.
We conducted a trial in 42 benign and malignant meningiomas to assess a possible influence of preoperative dexamethasone therapy on mitotic index, labelling indices of proliferating cell nuclear antigen (PCNA), progesterone receptor, epidermal growth factor receptor (EGF-R), c-erbB-2 oncoprotein, cathepsin D, gamma-gamma enolase as well as the mean number of silver-stained nucleolar organizer region-associated proteins (AgNORs). Tumors with preceding dexamethasone therapy for more than 1 day display significantly less immunohistochemical staining for PCNA. A correlation between the labelling index of PCNA and the degree of malignancy could not be identified. There was no significant effect of preoperative dexamethasone therapy on the other parameters. Our data suggest that dexamethasone may selectively inhibit the expression of PCNA in the G1/S-phase of the cell cycle. Thus, we emphasize the necessity to heed factors, e.g. dexamethasone, which may affect the expression of proliferating markers.
我们对42例良性和恶性脑膜瘤进行了一项试验,以评估术前地塞米松治疗对有丝分裂指数、增殖细胞核抗原(PCNA)标记指数、孕酮受体、表皮生长因子受体(EGF-R)、c-erbB-2癌蛋白、组织蛋白酶D、γ-γ烯醇化酶以及银染核仁组织区相关蛋白(AgNORs)平均数量的可能影响。接受地塞米松治疗超过1天的肿瘤显示PCNA免疫组化染色明显减少。未发现PCNA标记指数与恶性程度之间存在相关性。术前地塞米松治疗对其他参数无显著影响。我们的数据表明,地塞米松可能在细胞周期的G1/S期选择性抑制PCNA的表达。因此,我们强调需要注意可能影响增殖标志物表达的因素,例如地塞米松。